Streetbeat News

SVRA

Savara Inc.

https://www.savarapharma.com

Industry

Biotechnology

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

Savara announced the acceptance of an abstract for a poster presentation at the European Respiratory Society Congress 2024 in Vienna. The company will present results from the IMPALA-2 study on inhaled Molgramostim for autoimmune pulmonary alveolar proteinosis and sponsor an industry symposium.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2024 | 12:23 pm

HC Wainwright & Co. analyst Andrew Fein has reiterated a Buy rating on Savara (NASDAQ:SVRA) and maintained a $10 price target.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 6:15 pm

JMP Securities analyst Jonathan Wolleben maintains a Market Outperform rating on Savara (NASDAQ:SVRA) but lowers the price target from $10 to $9.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 11:51 am

Savara (NASDAQ:SVRA) reported a Q2 2024 adjusted EPS of $(0.12), missing the analyst consensus estimate of $(0.11) by 9.09%.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 8:06 pm

Savara Inc. (NASDAQ:SVRA) announced the pricing of a $100 million underwritten offering of 26,246,720 shares of its common stock at $3.81 per share. The offering is expected to close on July 1, 2024, and includes investors such as Bain Capital Life Sciences and Wellington Management.

Portfolio Pulse from Benzinga Newsdesk

June 28, 2024 | 12:50 pm

Guggenheim analyst Daniel Krizay maintains a Buy rating on Savara (NASDAQ:SVRA) and raises the price target from $8 to $10.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2024 | 5:29 pm

HC Wainwright & Co. analyst Andrew Fein maintains a Buy rating on Savara (NASDAQ:SVRA) and raises the price target from $6 to $10.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2024 | 10:11 am

Oppenheimer analyst Francois Brisebois maintains an Outperform rating on Savara (NASDAQ:SVRA) and raises the price target from $11 to $15.

Portfolio Pulse from Benzinga Newsdesk

June 26, 2024 | 5:30 pm

Savara shares are trading lower after initially rising on the results of their Phase 3 IMPALA-2 clinical trial.

Portfolio Pulse from Benzinga Newsdesk

June 26, 2024 | 4:56 pm

Savara Inc (NASDAQ: SVRA) announced that its Phase 3 IMPALA-2 trial for molgramostim, a treatment for autoimmune pulmonary alveolar proteinosis (aPAP), met its primary endpoint. The trial showed statistically significant improvements in lung function and quality of life measures. As a result, SVRA shares surged 30% in premarket trading.

Portfolio Pulse from Vandana Singh

June 26, 2024 | 1:36 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.